1. Home
  2. PLUG vs KLRA Comparison

PLUG vs KLRA Comparison

Compare PLUG & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plug Power Inc.

PLUG

Plug Power Inc.

HOLD

Current Price

$2.29

Market Cap

2.9B

Sector

Energy

ML Signal

HOLD

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$17.28

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUG
KLRA
Founded
1997
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
1999
2026

Fundamental Metrics

Financial Performance
Metric
PLUG
KLRA
Price
$2.29
$17.28
Analyst Decision
Hold
Analyst Count
11
0
Target Price
$2.31
N/A
AVG Volume (30 Days)
57.5M
525.5K
Earning Date
05-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
47.01
N/A
EPS
N/A
N/A
Revenue
$709,919,000.00
N/A
Revenue This Year
$26.67
N/A
Revenue Next Year
$8.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.90
N/A
52 Week Low
$1.41
$16.39
52 Week High
$4.58
$23.82

Technical Indicators

Market Signals
Indicator
PLUG
KLRA
Relative Strength Index (RSI) 52.57 40.25
Support Level $2.11 $16.39
Resistance Level $2.50 $19.13
Average True Range (ATR) 0.15 1.00
MACD 0.03 0.05
Stochastic Oscillator 54.37 9.83

Price Performance

Historical Comparison
PLUG
KLRA

About PLUG Plug Power Inc.

Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Share on Social Networks: